UP!

ANAC $65.55   View long term graphs

Anacor Pharmaceuticals Inc.
Type
Public
Traded as NASDAQ: ANAC
Industry Pharmaceutical
Fate Acquired by Pfizer
Key people
Paul L. Berns (CEO)
Website anacor.com

Anacor Pharmaceuticals is a biopharmaceutical company focused on discovering, developing and commercializing novel small-molecule therapeutics derived from its boron chemistry platform. It is based in Palo Alto, California, United States. Anacor was founded in 2002 based on technology created by Lucy Shapiro at Stanford University and Stephen Benkovic at Pennsylvania State University. Cofounder David Perry served as CEO and President from 2002 to 2014, and took the company public in 2010. Since then, the company has generated a pipeline of both topical and systemic boron-based compounds of which five are currently in clinical development.

In May 2016, Pfizer announced it would acquire Anacor Pharmaceuticals for $5.2 billion, expanding the company's portfolio in both inflammation and immunology drugs areas.

Boron is a naturally occurring element in the environment, but relative to carbon, hydrogen, nitrogen and oxygen, little research has been done on the role of boron in therapeutics because of the limited understanding of the physical properties necessary to provide boron-based compounds with the attributes required of pharmaceutical therapies as well as difficulty in chemical synthesis. However, boron has two qualities that give it advantages in the small-molecule drug discovery process. First, boron has a unique geometry that allows compounds made from it to have two distinct shapes, giving boron-based drugs the ability to interact with biological targets in novel ways and to address targets not amenable to intervention by traditional carbon-based compounds. And second, boron's enhanced reactivity as compared to carbon allows the molecules to hit targets that are difficult to inhibit with carbon chemistry.

Tavaborole is a topical antifungal drug for the treatment of onychomycosis, a fungal infection of the nail and nail bed. Anacor began its Phase 3 trials in December 2010. Tavaborole inhibits an essential fungal enzyme, leucyl-transfer RNA synthetase, or LeuRS, required for protein synthesis. The inhibition of protein synthesis leads to termination of cell growth and cell death, eliminating the fungal infection. No treatment-related systemic side effects have been observed in any of its clinical trials. It gained FDA approval in July 2014.

Crisaborole Topical Ointment 2% is a topical anti-inflammatory product for the treatment of psoriasis and atopic dermatitis. Crisaborole Topical Ointment 2% inhibits PDE4 and reduces the production of TNF-alpha, a precursor of the inflammation associated with psoriasis as well as other cytokines, including IL-12 and IL-23, which are proteins believed to be involved in the inflammation process and immune responses. Crisaborole Topical Ointment 2% is currently in Phase 2b for psoriasis and Phase 3 for atopic dermatitis.

News

Anacor Pharmaceuticals, Inc. -4.97% (healthcare)

Q reports

Period Date Adjusted Actuals EPS GAAP EPS
Q3 2016 2016-11-07 Future report Set alerts
Q2 2016 2016-08-04 Future report Set alerts
Q1 2016 2016-05-10 -0.36 -0.36
Q4 2015 2016-02-29 -0.43 -0.43
Q3 2015 2015-11-03 -0.37 -0.37
Q2 2015 2015-08-06 -0.30 -0.30
Q1 2015 2015-05-06 -0.30 -0.30
Q4 2014 2015-03-12 -0.24 -0.24
Q3 2014 2014-11-06 -0.74 -0.74
Q2 2014 2014-08-07 -0.58 -0.58

Ratings

2016-05-18 Downgrade Mizuho Buy to Neutral $98.00 to $99.25
2016-05-16 Reiterated Rating Jefferies Group Buy
2016-05-16 Downgrade Wedbush Outperform to Neutral $148.00 to $99.25
2016-05-10 Reiterated Rating Mizuho Buy $95.00
2016-05-10 Reiterated Rating Cowen and Company Buy
2016-05-10 Reiterated Rating Wedbush Outperform $148.00
2016-05-02 Reiterated Rating Wedbush Outperform $152.00 to $148.00
2016-04-21 Reiterated Rating Jefferies Group Buy $105.00
2016-04-17 Reiterated Rating Cowen and Company Buy
2016-03-31 Reiterated Rating Mizuho Buy $102.00
2016-03-23 Reiterated Rating Mizuho Outperform $103.00 to $102.00
2016-03-11 Reiterated Rating Wedbush Outperform $152.00
2016-03-11 Initiated Coverage Mizuho Buy $103.00
2016-03-10 Reiterated Rating Jefferies Group Buy $105.00
2016-03-01 Reiterated Rating Cowen and Company Outperform
2016-03-01 Reiterated Rating Jefferies Group Buy $105.00
2016-02-26 Reiterated Rating Wedbush Outperform $190.00
2016-02-24 Reiterated Rating Cowen and Company Outperform
2016-01-15 Reiterated Rating Wedbush Outperform $190.00
2016-01-07 Reiterated Rating Wedbush Outperform $190.00
2015-12-28 Reiterated Rating Wedbush Outperform $190.00
2015-12-18 Reiterated Rating Wedbush Outperform $190.00
2015-12-04 Reiterated Rating Wedbush Outperform $190.00
2015-10-22 Reiterated Rating Jefferies Group Buy $171.00
2015-09-09 Initiated Coverage JMP Securities Outperform $173.00
2015-07-21 Upgrade Bank of America Neutral to Buy
2015-07-21 Upgrade Goldman Sachs Neutral to Buy $195.00
2015-07-21 Upgrade Bank of America Corp. Neutral to Buy
2015-07-21 Upgrade Goldman Sachs Group Inc. Neutral to Buy $195.00
2015-07-14 Boost Price Target Jefferies Group Buy $80.00 to $171.00
2015-07-01 Boost Price Target Jefferies Group Buy $70.00 to $80.00
2015-06-30 Boost Price Target Wedbush Outperform $72.00 to $85.00
2015-05-04 Boost Price Target Jefferies Group Buy $57.00 to $70.00
2015-04-21 Boost Price Target Wedbush Buy $72.00
2015-03-13 Boost Price Target Jefferies Group Buy $41.00 to $57.00
2015-03-13 Boost Price Target Wedbush Outperform $50.00 to $60.00
2015-02-16 Reiterated Rating Wedbush Outperform $50.00
2015-02-03 Boost Price Target Wedbush $50.00
2015-01-26 Boost Price Target Jefferies Group Buy $34.00 to $41.00
2014-12-17 Initiated Coverage Goldman Sachs Neutral $36.00
2014-09-09 Initiated Coverage Avondale Partners Outperform
2014-08-08 Boost Price Target Jefferies Group Buy $24.00 to $25.00
2014-05-15 Reiterated Rating Jefferies Group Buy $24.00
2014-05-07 Reiterated Rating Jefferies Group Buy $24.00
2014-04-29 Reiterated Rating Jefferies Group Buy $24.00
2014-04-21 Initiated Coverage Jefferies Group Buy $24.00
2013-10-29 Boost Price Target Canaccord Genuity Buy $17.00 to $24.00
2013-10-21 Boost Price Target Canaccord Genuity Buy $13.00 to $17.00
2013-10-18 Boost Price Target Wedbush $20.00 to $29.00
2013-10-18 Boost Price Target Deutsche Bank Buy $11.00 to $20.00
2013-01-30 Reiterated Canaccord Genuity Buy $9 to $5
2016-05-18 Downgrade Mizuho Buy to Neutral $98.00 to $99.25
2016-05-16 Reiterated Rating Jefferies Group Buy
2016-05-16 Downgrade Wedbush Outperform to Neutral $148.00 to $99.25
2016-05-10 Reiterated Rating Mizuho Buy $95.00
2016-05-10 Reiterated Rating Cowen and Company Buy

There is presents forecasts of rating agencies and recommendations for investors about this ticker

Funds

In ANAC 5 funds of 2183 total. Show all

Fund name Ticker shares
Apex Capital Management 0.24M
RUSSELL FRANK CO/ 0.23M
MANAGED ACCOUNT ADVISORS LLC 84541
BAIRD ROBERT W & CO INC /WI/ 66958
SHAPIRO ROBERT N 26724

Major Shareholders

Name Relationship Total Shares Holding stocks
VENROCK ASSOCIATES V LP 8.87%  (3725535) ANAC / CERU / CSLT / FATE / RCPT / ZLTQ /
VENROCK ASSOCIATES IV L P 8.51%  (3575535) AKAO / ANAC /
PERRY DAVID P President and CEO 0.86%  (361306) ANAC /
RHO VENTURES IV LP 0.58%  (243815) ANAC / IL /
Parker Geoffrey M. Senior Vice President and CFO 0.41%  (173000) ANAC / CCXI / GHDX / PRGO / SNSS /
Chanda Sanjay VP, Int. Head of Drug Dev. 0.07%  (29087) ANAC /
Plattner Jacob j Senior VP, Research 0.04%  (17840) ANAC /
Maples Kirk R SVP, Program Management 0.02%  (7220) ANAC /
Rodriguez Carmen R Snr VP Reg Afrs & Qual. Assur. 0.02%  (7020) ANAC /

Comments